Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Maciej Banach"'
Publikováno v:
Expert opinion on pharmacotherapy. 21(10)
According to current guidelines, malignant hypertension is one of the emergencies in hypertension. The definition requires the presence of bilateral retinal hemorrhages or exudates, with or without papilledema, acute heart failure and acute deteriora
Publikováno v:
Expert Opinion on Pharmacotherapy. 18:377-386
Current guidelines for pharmacotherapy briefly describe a role for combination antihypertensive therapy. However, guidance on whether combination therapy should be used at the time of initiating therapy or as add on, and the choice of combination the
Autor:
Cesare R. Sirtori, Massimiliano Ruscica, Maciej Banach, Alberto Corsini, Amirhossein Sahebkar
Publikováno v:
Expert opinion on pharmacotherapy. 20(7)
Tolerability problems in treating hypercholesterolemic patients undergoing statin treatment are of growing concern to physicians and patients, thus underlining the need for an agent with a similar mechanism but minimal side effects. A drug with a som
Autor:
Maciej Banach, Beata Franczyk, Łukasz Jurkiewicz, Anna Gluba-Brzózka, Jacek Rysz, Peter E. Penson
Publikováno v:
Expert opinion on pharmacotherapy. 19(17)
INTRODUCTION: Cardiovascular disease (CVD) is an important cause of mortality and morbidity worldwide. CVD morbidity and mortality are associated with significant financial costs related to hospitalization, medication, and lost productivity. The conc
Publikováno v:
Expert opinion on pharmacotherapy. 17(15)
Despite progress in the understanding of pathogenetic mechanisms of organ cyst formation in autosomal dominant polycystic kidney disease, current treatment methods are insufficient. Experimental studies and clinical trials target at inhibition of cys
Publikováno v:
Expert opinion on pharmacotherapy. 17(11)
Statin intolerance is largely defined by muscle related symptoms, leading to intolerability and cessation. The nocebo effect coupled with the challenges of diagnosing statin myopathy undermines drug adherence that is critical for achieving the benefi
Publikováno v:
Expert opinion on pharmacotherapy. 17(3)
A residual risk of morbidity and mortality from cardiovascular (CV) disease remains despite statin therapy. This situation has generated an interest in finding novel approaches of combining statins with other lipid-lowering agents, or finding new lip
Publikováno v:
Expert Opinion on Pharmacotherapy. 12:2329-2338
Chronic heart failure (CHF) is the only major cardiovascular disease whose prevalence and incidence are thought to be increasing. Potassium balance may be lost both through the neurohormonal mechanisms involved in cardiovascular diseases and through
Publikováno v:
Expert Opinion on Pharmacotherapy. 11:2665-2674
Patients with end-stage renal disease are at high risk of developing cardiovascular disease, which is characterized by early onset and rapid progression of atherosclerosis. Some analyses of large clinical trials have revealed that statins might reduc
Autor:
Jolanta Malyszko, Dimitri P. Mikhailidis, Maciej Banach, Marta Michalska, Jacek Rysz, Sverre E. Kjeldsen
Publikováno v:
Expert opinion on pharmacotherapy. 12(12)
The blood pressure (BP) J-curve debate has lasted for over 30 years and we still cannot definitively answer all the questions. However, recent studies suggest that BP should be reduced carefully in patients with hypertension and coronary artery disea